These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: an in vitro stability assessment. Veurink M, Stella C, Tabatabay C, Pournaras CJ, Gurny R. Eur J Pharm Biopharm; 2011 Jun; 78(2):271-7. PubMed ID: 21172437 [Abstract] [Full Text] [Related]
4. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Sheth S, Rush R, Natarajan S, Gillies M. Clin Exp Ophthalmol; 2011 Jun; 39(7):673-81. PubMed ID: 22452685 [Abstract] [Full Text] [Related]
5. Validation of an automated method for compounding monoclonal antibody patient doses: case studies of Avastin (bevacizumab), Remicade (infliximab) and Herceptin (trastuzumab). Peters BJ, Capelle MA, Arvinte T, van de Garde EM. MAbs; 2013 Jun; 5(1):162-70. PubMed ID: 23255057 [Abstract] [Full Text] [Related]
6. Development and validation of aggregates analysis method in analytical similarity assessment of HLX04 vs Avastin®. Fei M, Zhang Q, Zhang L, Zhu X, Du C, Zhang Z. J Pharm Biomed Anal; 2023 Jan 20; 223():115121. PubMed ID: 36308924 [Abstract] [Full Text] [Related]
8. Aggregation of biopharmaceuticals in human plasma and human serum: implications for drug research and development. Arvinte T, Palais C, Green-Trexler E, Gregory S, Mach H, Narasimhan C, Shameem M. MAbs; 2013 Jan 20; 5(3):491-500. PubMed ID: 23571158 [Abstract] [Full Text] [Related]
14. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. De Nardis C, Hendriks LJA, Poirier E, Arvinte T, Gros P, Bakker ABH, de Kruif J. J Biol Chem; 2017 Sep 01; 292(35):14706-14717. PubMed ID: 28655766 [Abstract] [Full Text] [Related]
15. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion. Wu WC, Cheng KC, Wu HJ. Eye (Lond); 2009 Dec 01; 23(12):2215-22. PubMed ID: 19218991 [Abstract] [Full Text] [Related]
16. Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema: a prospective randomized comparison. Gado AS, Macky TA. Clin Exp Ophthalmol; 2014 Dec 01; 42(7):650-5. PubMed ID: 24612095 [Abstract] [Full Text] [Related]
17. Quantitative evaluation of hard exudates in diabetic macular edema after short-term intravitreal triamcinolone, dexamethasone implant or bevacizumab injections. Shin YU, Hong EH, Lim HW, Kang MH, Seong M, Cho H. BMC Ophthalmol; 2017 Oct 03; 17(1):182. PubMed ID: 28974211 [Abstract] [Full Text] [Related]
18. [Complications of intravitreal injections--own experience]. Jamrozy-Witkowska A, Kowalska K, Jankowska-Lech I, Terelak-Borys B, Nowosielska A, Grabska-Liberek I. Klin Oczna; 2011 Oct 03; 113(4-6):127-31. PubMed ID: 21913440 [Abstract] [Full Text] [Related]
19. Embryo-fetal transfer of bevacizumab (Avastin) in the rat over the course of gestation and the impact of neonatal Fc receptor (FcRn) binding. Thorn M, Piche-Nicholas N, Stedman D, Davenport SW, Zhang N, Collinge M, Bowman CJ. Birth Defects Res B Dev Reprod Toxicol; 2012 Oct 03; 95(5):363-75. PubMed ID: 22969064 [Abstract] [Full Text] [Related]
20. Larger therapeutic window for steroid versus VEGF-A inhibitor in inflammatory angiogenesis: surprisingly similar impact on leukocyte infiltration. Nakao S, Zandi S, Lara-Castillo N, Taher M, Ishibashi T, Hafezi-Moghadam A. Invest Ophthalmol Vis Sci; 2012 Jun 05; 53(7):3296-302. PubMed ID: 22427602 [Abstract] [Full Text] [Related] Page: [Next] [New Search]